138 related articles for article (PubMed ID: 25427744)
1. CEACAM6 as detected by the AP11 antibody is a marker notable for mucin-producing adenocarcinomas.
Lee OJ; Son SM; Hong KP; Lee YM; Kim MY; Choi JW; Lee SJ; Song YJ; Kim HS; Kim WJ; Shin SO; Song HG
Virchows Arch; 2015 Feb; 466(2):151-9. PubMed ID: 25427744
[TBL] [Abstract][Full Text] [Related]
2. A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched.
Balk-Møller E; Kim J; Hopkinson B; Timmermans-Wielenga V; Petersen OW; Villadsen R
Am J Pathol; 2014 Apr; 184(4):1198-208. PubMed ID: 24655379
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.
Litkouhi B; Litkouhi B; Fleming E; Welch WR; Berkowitz RS; Birrer MJ; Mok SC
Gynecol Oncol; 2008 May; 109(2):234-9. PubMed ID: 18331757
[TBL] [Abstract][Full Text] [Related]
4. Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers.
Blumenthal RD; Leon E; Hansen HJ; Goldenberg DM
BMC Cancer; 2007 Jan; 7():2. PubMed ID: 17201906
[TBL] [Abstract][Full Text] [Related]
5. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of anti CEACAM6 monoclonal antibody against lung adenocarcinoma by enhancing anoikis sensitivity.
Hong KP; Shin MH; Yoon S; Ji GY; Moon YR; Lee OJ; Choi SY; Lee YM; Koo JH; Lee HC; Lee GK; Kim SR; Lee KH; Han HS; Choe KH; Lee KM; Hong JM; Kim SW; Yi JH; Ji HJ; Kim YB; Song HG
Biomaterials; 2015 Oct; 67():32-41. PubMed ID: 26204223
[TBL] [Abstract][Full Text] [Related]
7. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary.
Hanski C; Hofmeier M; Schmitt-Gräff A; Riede E; Hanski ML; Borchard F; Sieber E; Niedobitek F; Foss HD; Stein H; Riecken EO
J Pathol; 1997 Aug; 182(4):385-91. PubMed ID: 9306958
[TBL] [Abstract][Full Text] [Related]
8. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach.
Tong AW; Lee J; Stone MJ
Cancer Res; 1984 Nov; 44(11):4987-92. PubMed ID: 6207911
[TBL] [Abstract][Full Text] [Related]
9. Expression profiling of CEACAM6 associated with the tumorigenesis and progression in gastric adenocarcinoma.
Deng X; Liu P; Zhao Y; Wang Q
Genet Mol Res; 2014 Sep; 13(3):7686-97. PubMed ID: 25299082
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 trans-signaling increases the expression of carcinoembryonic antigen-related cell adhesion molecules 5 and 6 in colorectal cancer cells.
Holmer R; Wätzig GH; Tiwari S; Rose-John S; Kalthoff H
BMC Cancer; 2015 Dec; 15():975. PubMed ID: 26673628
[TBL] [Abstract][Full Text] [Related]
11. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue.
Shih IM; Nesbit M; Herlyn M; Kurman RJ
Mod Pathol; 1998 Nov; 11(11):1098-106. PubMed ID: 9831208
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in colorectal cancer.
Kim KS; Kim JT; Lee SJ; Kang MA; Choe IS; Kang YH; Kim SY; Yeom YI; Lee YH; Kim JH; Kim KH; Kim CN; Kim JW; Nam MS; Lee HG
Clin Chim Acta; 2013 Jan; 415():12-9. PubMed ID: 22975528
[TBL] [Abstract][Full Text] [Related]
13. Three novel mouse monoclonal antibodies, OM-A, OM-B, and OM-C, reactive with mucinous type ovarian tumors.
Sakakibara K; Ueda R; Ohta M; Nakashima N; Tomoda Y; Takahashi T
Cancer Res; 1988 Aug; 48(16):4639-45. PubMed ID: 2456145
[TBL] [Abstract][Full Text] [Related]
14. ES1, a new lung carcinoma antibody--an immunohistochemical study.
Mai KT; Perkins DG; Zhang J; Mackenzie CR
Histopathology; 2006 Nov; 49(5):515-22. PubMed ID: 17064298
[TBL] [Abstract][Full Text] [Related]
15. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.
Moll R; Löwe A; Laufer J; Franke WW
Am J Pathol; 1992 Feb; 140(2):427-47. PubMed ID: 1371204
[TBL] [Abstract][Full Text] [Related]
17. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.
Krueger P; Nitz C; Foster R; MacDonald C; Gelber O; Lalehzadeh G; Goodson R; Winter J; Gelber C
Cancer Immunol Immunother; 2003 Jun; 52(6):367-77. PubMed ID: 12669243
[TBL] [Abstract][Full Text] [Related]
18. [Nonspecific cross-reacting antigen (NCA)--carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6)].
Hayashi T; Shinomura Y; Imai K
Nihon Rinsho; 2010 Jul; 68 Suppl 7():753-5. PubMed ID: 20960864
[No Abstract] [Full Text] [Related]
19. CEACAM6 is upregulated by Helicobacter pylori CagA and is a biomarker for early gastric cancer.
Roy RK; Hoppe MM; Srivastava S; Samanta A; Sharma N; Tan KT; Yang H; Voon DC; Pang B; Teh M; Murata-Kamiya N; Hatakeyama M; Chang YT; Yong WP; Ito Y; Ho KY; Tan P; Soong R; Koeffler PH; Yeoh KG; Jeyasekharan AD
Oncotarget; 2016 Aug; 7(34):55290-55301. PubMed ID: 27421133
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a CEACAM6-targeting theranostic nanomedicine for photoacoustic-based diagnosis and chemotherapy of metastatic cancer.
Lee H; Jang Y; Park S; Jang H; Park EJ; Kim HJ; Kim H
Theranostics; 2018; 8(15):4247-4261. PubMed ID: 30128051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
